Abstract
Envafolimab (恩维达®) is a subcutaneously (SC) administered single domain anti-programmed death ligand 1 (PD-L1) antibody being developed for the treatment of various solid tumours and chronic hepatitis B in China, and for soft tissue sarcomas and biliary tract cancer in the USA. Single-domain antibodies are more soluble and more rapidly penetrate tissues than full monoclonal antibodies, enabling SC administration. Based on the results of a pivotal phase II trial, SC envafolimab was recently approved in China for the treatment of adult patients with previously-treated microsatellite instability-high (MSI-H) or deficient MisMatch Repair (dMMR) advanced solid tumours. This article summarizes the milestones in the development of envafolimab leading to this first approval.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Li J, Deng Y, Zhang W, et al. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors. J Hematol Oncol. 2021. https://doi.org/10.1186/s13045-021-01095-1.
Alphamab Oncology. Envafolimab, the world’s first subcutaneously injected PD-L1 antibody approved by NMPA! Alphamab Oncology partners with 3DMed and Simcere to innovate immunotherapy [media release]. Nov 26 2021. http://www.alphamabonc.com/en/html/news/2375.html.
3D Medicines, Suzhou Alphamab. Global first IND for subcutaneous injectable anti-PD-L1 domain antibody receives FDA approval [media release]. 30 Nov 2016.
Ascletis. Ascletis and Alphamab announce strategic collaboration and licensing agreement for anti-PD-L1 to treat hepatitis B and other viral diseases [media release]. 13 Jan 2019.
Tracon Pharmaceuticals. TRACON Pharmaceuticals, 3D Medicines and Jiangsu Alphamab announce partnership for development of subcutaneous PD-L1 single-domain antibody in soft tissue sarcoma [media release]. 20 Dec 2019.
Alphamab Oncology. Alphamab Oncology, Simcere and 3D Medicines announce partnership to develop and commercialize subcutaneous injectable anti-PD-L1 antibody for oncology indications in mainland China [media release]. 30 Mar 2020.
Zhang F, Wei H, Wang X, et al. Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade. Cell Discov. 2017;3:17004.
Papadopoulos KP, Harb W, Peer CJ, et al. First-in-human phase I study of envafolimab, a novel subcutaneous single-domain anti-PD-L1 antibody, in patients with advanced solid tumors. Oncologist. 2021;26(9):e1514–25.
Shen L, Li J, Deng Y, et al. Envafolimab (KN035) monotherapy in MSI-H/dMMR advanced entities, data from a single-arm, multicenter phase II study of efficacy and safety in cancer [abstract]. In: Chinese Society of Clinical Oncology Annual Meeting. 2021.
Xu JM, Qin S, Zhang Y, et al. Phase I study of KN035, the first subcutaneously administered, novel fusion anti-PD-L1 antibody in patients with advanced solid tumors in China [abstract no. 2608]. J Clin Oncol Conf. 2019;37(Suppl 15).
Shimizu T, Nakajima TE, Lu N, et al. Phase I safety and pharmacokinetic study of KN035, the first subcutaneously administered, novel fusion anti-PD-L1 antibody in Japanese patients with advanced solid tumors [abstract no. 2609]. J Clin Oncol Conf. 2019;37(Suppl 15).
Yin X, Zhang Y, Deng Y, et al. Envafolimab plus chemotherapy in advanced gastric or gastroesophageal junction (G/GEJ) cancer [abstract no. e16585]. J Clin Oncol Conf. 2020;38(15).
Wang G, Qian J, Cui Y, et al. A phase IIa trial of subcutaneously administered pd-l1 antibody ASC22 (envafolimab) in patients with chronic hepatitis B [abstract no. 91]. Hepatology. 2021;74(Suppl 1):62A.
D'Angelo SP, Robinson SI, Lam J, et al. ENVASARC: a pivotal trial of envafolimab, and envafolimab in combination with ipilimumab, in patients with advanced or metastatic undifferentiated pleomorphic sarcoma or myxofibrosarcoma who have progressed on prior chemotherapy [abstract no. TPS11581]. J Clin Oncol Conf: Annual Meeting of the American Society of Clinical Oncology, ASCO. 2021;39(Suppl 15).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
The preparation of this review was not supported by any external funding.
Authorship and Conflict of interest
During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. A. Markham is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.
Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability
Not applicable.
Additional information
This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Markham, A. Envafolimab: First Approval. Drugs 82, 235–240 (2022). https://doi.org/10.1007/s40265-022-01671-w
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40265-022-01671-w